Mukai, Hirofumi http://orcid.org/0000-0002-9292-5128
Uemura, Yukari
Akabane, Hiromitsu
Watanabe, Takanori
Park, Youngjin
Takahashi, Masato
Sagara, Yoshiaki
Nishimura, Reiki
Takashima, Tsutomu
Fujisawa, Tomomi
Hozumi, Yasuo
Kawahara, Takuya
Article History
Received: 26 September 2019
Revised: 15 April 2021
Accepted: 18 August 2021
First Online: 3 September 2021
Ethics approval and consent to participate
: The studies were done in accordance with the Ethical Guidelines for Clinical Research of the Japanese Ministry of Health, Labor and Welfare, and the Declaration of Helsinki. All participants gave written informed consent. An independent ethics committee for each participating site approved the protocol and any modifications. A full list of the ethical committees can be found in the Supplementary Information.
: Not applicable.
: HM has received personal fees from Daiichi Sankyo, Taiho, and Takeda; funding from the Japanese government, Pfizer, and Daiichi Sankyo, outside the submitted work. MT has received personal fees from Taiho, Eisai, Pfizer, Astra Zeneca, Kyowa Kirin, Nippon Kayaku and Eli Lilly. TT has received personal fees from Taiho, Chugai Kyowa Hakko Kirin, Eisai, Pfizer, Novartis, Astra Zeneca and Takeda, outside the submitted work. The remaining authors declare no competing interests.